Targeted tumour therapy is in the focus of recent cancer research. GnRH analogues are able to deliver anticancer agents selectively into tumour cells which highly express GnRH receptors. However, the effectiveness of different analogues as targeting moiety in drug delivery systems is rarely compared and the investigated types of cancers are also limited. Therefore, we prepared selectively labelled, fluorescent derivatives of GnRH-I, -II, and -III analogues which successfully used for drug targeting. In this manuscript we investigated these analogues solubility, stability, passive membrane permeability and compared their cellular uptake by various cancer cells.
Synthesis, characterisation and systematic comparison of FITC-labelled GnRH-I, -II and -III analogues on various tumour cells
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Introduction
Cancer is the second leading cause of death in the developed countries [1] . Among treatment options for cancer one of the most promising and developing procedure is the targeted chemotherapy, based on the tumour selective or over-expressed receptors. The high expression of gonadotropin releasing hormone receptor (also called luteinizing hormone releasing hormone receptor) has been identified in many types of cancer [2] [3] [4] . Therefore the natural and artificial ligands of GnRH receptors are extensively studied as tumour targeting systems [5] [6] [7] [8] .
Human pituitary GnRH-R has crucial role in the control of the reproductive system, and it is a well-known molecular target in the treatment of reproduction-related diseases [9] . GnRH analogues are widely and successfully used for the treatment of different hormone related pathologies based on their ability to suppress the hypothalamic-pituitary-gonadal axis [10] .
GnRH receptors are also expressed in number of cancer tissues, either related or unrelated to the reproductive system [11] . It was indicated that GnRH and its receptors are a part of an autocrine/paracrine regulatory system of cell proliferation in malignant tumours [11] [12] [13] . In addition, the proliferation can be inhibited by agonist or antagonist analogues of GnRH in a dose and time dependent manner both in vitro and in vivo [12, 14] . Furthermore, GnRH derivatives can be used as homing devices to deliver anticancer drugs into cancer cells expressing GnRH receptors [15] . Cytotoxic drug -GnRH conjugates could dramatically improve the antitumour efficiency of GnRH analogues and represent a very promising therapeutic approach for certain tumours. Schally and co-workers developed potent GnRHdrug conjugates, including [D-Lys 6 ]-GnRH-I-doxorubicin which is in Phase II or III Clinical
Trial for several types of cancer [8] .
Besides GnRH-I, a second native isoform of GnRH (first isolated from chicken (Gallus gallus domesticus) [16] ) was identified in humans [17] . The GnRH-II receptor was revealed in various species including nonhuman primates, but the existence of GnRH-II receptor in the human organism is still controversial [18] . Fister and co-workers reported that GnRH-II antagonists are able to bind to the GnRH-I receptor (GnRH-I-R), and their binding affinity are similar to the GnRH-I antagonist Cetrorelix [19] . Furthermore, Montagnani et al. reported that the effect of GnRH-II was mediated by GnRH-I-R on prostate cancer cells [20] . GnRH-II had strong antiproliferative effect and induced apoptosis in endometrial, ovarian, breast and prostate cancer cell lines as well [18] [19] [20] [21] . Gründker et al. reported that on the human ovarian cancer cell line SK-OV-3, which does not express GnRH-I-R, the GnRH-I antagonist Cetrorelix and GnRH-II had strong antiproliferative effect [22] . These results suggested that the antiproliferative effect of GnRH-II in endometrial and ovarian cancer cells were not mediated through the GnRH-I-R [22] . Therefore, the GnRH-I-R seems not to be the only target for GnRH-II agonists on certain cancer cells [18] . Besides, the cytotoxic conjugates of [D-Lys 6 ]-GnRH-II were also described to be effective antitumour agents [23] .
A third isoform of GnRH was isolated from sea lamprey (Petromyzon marinus) [24] .
Lamprey GnRH-III binds to both GnRH-I and GnRH-II receptors but with lower efficacy than their native ligands [25] . Therefore, it is a weak GnRH agonist which has insignificant endocrine effect in mammals. In addition it can recognize not only the high-, but also the lowaffinity binding sites of GnRH receptors on cancer cells [25] . In experimental setups, GnRH-III significantly suppressed the proliferation of human cancer cells which overexpress GnRH-R [26] . Therefore, also daunorubicin containing GnRH-III conjugates were synthesized and investigated in vitro and in vivo [27] [28] [29] . These conjugates were well tolerated and had significant antitumour effect on colon carcinoma-bearing mice [29] . On castration-resistant prostate cancer cells GnRH-III-daunorubicin conjugates inhibited tumour cell proliferation and exerted their antitumour effect through the activation of GnRH-I-R [28] . Based on these observations GnRH-III-based peptides are considered promising targeting moieties for the preparation of anticancer drug delivery systems.
Although hundreds of publications has been reported about GnRH and GnRH conjugates since it was discovered [30] , there are only a few experiments with fluorescently labelled GnRH derivatives [31] . The variety of the tested cell lines has been also limited yet, and the results coming out from different studies are usually not comparable due to the different experimental parameters.
Our idea was that benefits of fluorescently-labelled GnRH analogues could contribute to the development of novel tumour targeting GnRH-drug conjugates, besides could help to identify new therapeutic targets and offer novel information about these peptides. Indeed, selectively labelled peptides have excellent tracking properties and allow their reliable quantification.
Quantifying the uptake of these analogues may predict the adequacy of a given cancer culture for GnRH targeted therapy.
Based on these considerations we selected three effective GnRH analogues, which and their characterization, solubility, stability, cellular permeability, cytotoxicity and cellular uptake properties were studied. To demonstrate the usability of these conjugates, we tested them on GnRH-I-R expressing LNCaP (prostate), MCF-7 (breast), BxPC-3 (pancreas) and HT-29 (colon) tumour cell lines [18, [32] [33] [34] , and involved a previously not investigated pharynx tumour cell line, the Detroit-562 into the experiments. We investigated the presence of the GnRH-I-R on the featured pharynx tumour and evaluated its susceptibility for GnRH targeted therapy.
Materials and Methods

Synthesis of FITC labelled GnRH conjugates
All amino acid derivatives and reagents were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary). The solvents (acetonitrile, ethanol, methanol, pyridine, diethyl-ether, DCM, DMF)
were purchased from Reanal Ltd. (Budapest, Hungary). All reagents and solvents were reagent grade or the highest available purity.
GnRH peptides were synthesized manually on H-Rink Amide ChemMatrix ® resin using standard Fmoc strategy. The following amino acid derivatives were applied: Fmoc-Gly-OH, were purified by semi-preparative RP-HPLC, and the pure compounds were characterized by analytical RP-HPLC and ESI-mass spectrometry.
High performance liquid chromatography
Analytical and preparative RP-HPLC were performed on a Jasco HPLC system (ABL&E-JASCO Hungary Ltd., Budapest, Hungary). The crude products were purified on a TFA in water) with eluent B (acetonitrile) was used at a flow rate of 1 mL/min. Peaks were detected by UV detector at λ=220 nm.
Mass spectrometry
Mass spectrometric analyses were carried out on a Waters Q-TOF Premier mass spectrometer (Waters Ltd., Budapest, Hungary). Electrospray ion source (ESI/MS) was used to perform MS measurements in positive ion mode in a range of 100-1800 Da. Samples were dissolved in acetonitrile/water (1:2 ratio) containing 0.1% TFA and introduced into the instrument. The ESI-MS conditions are detailed in the Supporting Information. 
Solubility experiment
Western blot analysis
Cells were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay 
Results and Discussion
GnRH analogues and their cytotoxic conjugates were reported as effective antitumour agents.
Numerous studies were published about GnRH based tumour targeting, and many 
Synthesis of FITC labelled GnRH Conjugates
All GnRH analogues were synthesized manually on H-Rink Amide ChemMatrix® resin using standard Fmoc strategy. After completing the synthesis of peptides, the protecting group was selectively removed from the side chain of Lys or D-Lys. After the FITC conjugation, the conjugates were cleaved form the resins. The conjugates ( Figure 1) were purified by semipreparative RP-HPLC, and characterized by HPLC-UV and ESI-MS ( Table 1 ).
The conjugates were identified by the triply charged ions ([M+3H] 3+ ). Tandem mass spectrometric data (fragment ions) and exact mass determination were used to confirm the structures. Based on the chromatographic data the purity of the conjugates were over 98%
( Figure S1 ). 
I (A), GnRH-II (B) and GnRH-III (C) derivatives
Solubility and stability evaluation of FITC-GnRH conjugates
The solubility parameters of FITC labelled and unlabelled GnRH analogues were compared in PBS (pH: 7.4, T: 25°C). Concentrations quantified by HPLC-UV ( Figure S2 ).
We found that the unlabelled GnRH analogues dissolved readily in PBS, their solubility being over 200 µM. Nevertheless, it was observed that the conjugation of FITC decreased the solubility of these peptides ( Table 2 Stability of the conjugates was measured in cell culture medium (RPMI) for 24 hours at 37°C.
During the experiment the stability of all compounds was detected by RP-HPLC, no additional peak appeared, and their purity remained higher than 98% ( Figure S2 ).
Permeability of FITC-GnRH conjugates
Permeability across biological membranes is a key factor in the absorption and distribution of conventional drugs, but it is undesired for targeted conjugates. We tested the permeability of our conjugates by PAMPA and MDCK permeability assay.
PAMPA has become a useful tool for predicting drug permeability driven by passive transport mechanisms. We used caffeine as positive and fluorescein sodium salt as negative control.
Compounds were tested at 40 µM concentration, and detected by UV-VIS spectroscopy ( Figure S3 ). We found that the conjugates and the fluorescein sodium salt had negligible permeability ( Table 3 MDCK cell lines provide a useful tool to predict the in vivo absorption of orally administered drugs. Compounds were tested at 10 µM concentration by MDCK permeability assay and detected by HPLC-UV ( Figure S4 ). We investigated both the "apical to basolateral", and the "basolateral to apical" transport directions. We found that the conjugates cannot penetrate the MDCK cell monolayer, detectable peaks were not observed in the receiver chambers
After these experiments we can conclude that the FITC labelled GnRH conjugates have negligible passive permeability. This observation corroborates the presumption, that the uptake of the conjugates takes place mainly by active transport mechanisms.
Cytotoxicity of FITC-GnRH conjugates
We tested the cytotoxicity of the labelled and the unlabelled GnRH analogues on the GnRH-I- 
GnRH-I-R analysis
The presence of GnRH-I-R has been previously demonstrated in LNCaP (prostate), MCF-7
(breast), BxPC-3 (pancreas) and HT-29 (colon) tumour cells by other groups [18, [32] [33] [34] . We 
Cellular uptake and cell surface GnRH-I-R analysis
The cell surface GnRH-I-R level was investigated by immunocytochemistry. We detected varying levels of GnRH-I-R on the surface of the different, non permeabilized tumour cells.
No 
Cellular uptake profile of FITC-GnRH conjugates
The cellular uptake profile of GnRH conjugates was studied by flow cytometer. We found that all of the labelled GnRH analogues were detectable in each of the tested cell lines at 10 µM, in correlation with the confocal microscopy experiments ( Figure 5 ).
The LNCaP (prostate) showed the highest uptake at 10 µM. The MCF-7 (breast) resulted high GnRH uptake also, its efficiency was similar to the Detroit-562 (pharynx). The MDCK (dog kidney), BxPC-3 (pancreas) and HT-29 (colon) took up the conjugates moderately ( Figure 5 ).
We observed that differences between the GnRH analogues were more significant at 1 µM, furthermore the different cells preferred different GnRH analogues (Table 4 ). This observation is in context with the "selective signaling theory", which means that "GnRH receptor can assume different conformations which have different selectivity for GnRH analogs" [36] . The previously not investigated Detroit-562 cells showed the highest uptake for GnRH-I and GnRH-III at 1 µM (Table 4) .
Our results proved better correlation between the uptake efficiency and the surface GnRH-I-R level at 1 µM, than 10 µM (Figure 4 and Figure 5 ). Significant cellular uptake was appeared for all conjugates at 10 µM on the GnRH-I-R negative MDCK and on the GnRH-I-R non exhibiting BxPC-3 cells also ( Figure 5 ). This suggests the presence of a GnRH-I-R independent uptake mechanism on these cell lines and predicts better GnRH-I-R selectivity for these conjugates below 10 µM. On the other hand the existence and the concentration dependent influence of the putative way is conceivable on other tested cell lines also, that should be further examined. This phenomenon correlates with the results were reported by Gründker et al. using human ovarian and endometrial cancers [18, 22] . 
Conclusions
Based on our present findings we can state that these novel, selectively labelled, fluorescent
GnRH derivatives are efficient tools to track and quantify their receptor mediated cellular uptake in vitro and predict the corresponding GnRH conjugates drug targeting efficiency in vivo. Experiments with these conjugates proved at first time that human pharynx tumours may also be promising targets for GnRH based therapy.
Our results confirm that each of the three GnRH analogues are usable as drug delivery units, however different cells prefer different analogues. At the same time, we note that due to the lower endocrine activity and better solubility of GnRH-III, it might be preferable in hormone independent tumours' therapy.
We found that the effectiveness of the cellular uptake depends basically on the type of the tumour and on the applied concentration. The cellular uptake of GnRH analogues was well correlated with the level of cell surface GnRH-I-R at 1 µM. These results predict that these analogues have high GnRH-I-R selectivity below 1 µM. Furthermore, we suppose that the uptake of these GnRH peptides could take place not only by the human GnRH-I receptors, especially at higher concentrations (10 µM or above), but this unknown active transport mechanism should be further examined.
